Use of a Mobile Health App in Managing Pediatric Atopic Dermatitis
NCT ID: NCT06412094
Last Updated: 2024-05-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
66 participants
INTERVENTIONAL
2022-03-01
2022-12-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical vs. Anecdotal Evidence - Pediatric Atopic Dermatitis
NCT03559075
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
NCT03687359
Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis
NCT01093469
Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)
NCT03002571
Efficacy of the "Атопик Soothing Cream" in Children With Mild to Moderate Atopic Dermatitis
NCT02716181
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Outcome endpoints are objective severity assessment using the SCORAD scale, and subjective assessment of effectiveness using the POEM scale.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard care
Upon enrollment in the study at the end of the screening visit, participants in all groups receive a recommended treatment plan, according to the clinical severity of the AD, and. are instructed to contact the doctor via messenger for any questions related to their treatment.
Standard care
Recommendation of standard treatment plan, according to the clinical severity of the AD, and. are instruction to contact the doctor via messenger for any questions related to treatment recommendations.
Standard care with access to the "AtopicApp" mobile application
Subjects in the experimental and observational groups receive access to the "AtopicApp" mobile application, in addition to receiving standard medical care.
Standard care
Recommendation of standard treatment plan, according to the clinical severity of the AD, and. are instruction to contact the doctor via messenger for any questions related to treatment recommendations.
Access to the "AtopicApp" mobile application
Access to the "AtopicApp" mobile application with 1 day after enrollment.
Standard care with access to the "AtopicApp" mobile application with potential virtual oversight
The experimental group receives standard medical care, the AtopicApp mobile application, and information about doctor's virtual oversight through the app (monitoring registration and usage).
Standard care
Recommendation of standard treatment plan, according to the clinical severity of the AD, and. are instruction to contact the doctor via messenger for any questions related to treatment recommendations.
Access to the "AtopicApp" mobile application
Access to the "AtopicApp" mobile application with 1 day after enrollment.
Virtual oversight through the AtopicApp
Notification of doctor's virtual oversight through the AtopicApp mobile application.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard care
Recommendation of standard treatment plan, according to the clinical severity of the AD, and. are instruction to contact the doctor via messenger for any questions related to treatment recommendations.
Access to the "AtopicApp" mobile application
Access to the "AtopicApp" mobile application with 1 day after enrollment.
Virtual oversight through the AtopicApp
Notification of doctor's virtual oversight through the AtopicApp mobile application.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* participation in affiliated online Atopic School program
* presence of concomitant skin disease or pathological conditions that may affect the assessment of effectiveness (severe somatic diseases, mental disorders, oncologic or acute infectious diseases, etc.)
* avoidance from registration during consecutive 5 days following the screening visit (for participants in groups 2 or 3,)
4 Months
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Avanta Trading Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Natalia Migacheva, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Samara State Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samara State Medical University
Samara, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
242-SSMU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.